I-Mab is a leading clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative biologics for cancer and autoimmune disorders. With a robust pipeline and strong research capabilities, I-Mab is dedicated to addressing significant unmet medical needs in both domestic and international markets. The company's strategic focus on cutting-edge therapies positions it as a key player in the biopharmaceutical sector, with the potential to drive meaningful advancements in healthcare and improve patient outcomes.